Download presentation
Presentation is loading. Please wait.
Published byPhyllis Watkins Modified over 9 years ago
1
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease by Christoph Varenhorst, Stefan James, David Erlinge, John T. Brandt, Oscar Ö. Braun, Michael Man, Agneta Siegbahn, Joseph Walker, Lars Wallentin, Kenneth J. Winters, and Sandra L. Close EHJ Volume ():ehp157 May 9, 2009 Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org
2
Comparison of prasugrel 60 mg and clopidogrel 600 mg loading dose exposure of active metabolite by CYP2C19 genetic classification. Christoph Varenhorst et al. Eur Heart J 2009;eurheartj.ehp157 Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org
3
Ratio RM/EM or difference (EM − RM) for pharmacokinetics and pharmacodynamic responses for CYP2C19, CYP2B6, CYP2C9, and CYP3A5. Christoph Varenhorst et al. Eur Heart J 2009;eurheartj.ehp157 Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org
4
Relationship between pharmacodynamic responses and CYP2C19 genetic classification measured by VASP assay (A) and VerifyNow™ P2Y12 device (B). Christoph Varenhorst et al. Eur Heart J 2009;eurheartj.ehp157 Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.